Podcast Special: Assessing US FDA Commissioner Robert Califf’s First 100 Days
Executive Summary
Reporters and editors from the Medtech Insight and sister publications covering the pharmaceutical and health, beauty and wellness sectors look at Califf’s goals, accomplishments and trials during the early days of his second term.
You may also be interested in...
Cardio Catch-Up: Medtech Innovation Takes Center Stage At TCT 2022
This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.
US Dietary Supplement Industry In 2023: Little New Expected In NDI Notification Enforcement
Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight concludes series here reporting on supplement sector’s outlook for FDA potentially resolving its protracted struggle with NDI notification requirement.
As COVID Public Health Emergency Winds Down, US FDA Employs Flexibility For Rx EUA Transitions
Biden administration sets May 11 as end date for public health emergency. CDER has said it will work with sponsors to help them gain approval of COVID therapeutics cleared under emergency use authorizations, but agency will likely not issue a formal transition framework.